  Facioscapulohumeral muscular dystrophy ( FSHD) is among the most prevalent of the adult-onset muscular dystrophies. FSHD causes a loss of muscle mass and function , resulting in severe debilitation and reduction in quality of life. Currently , only the symptoms of FSHD can be treated , and such treatments have minimal benefit. The available options are not curative , and none of the treatments address the underlying cause of FSHD. The genetic , epigenetic , and molecular mechanisms triggering FSHD are now quite well-understood , and it has been shown that expression of the transcriptional regulator